Testing misoprostol to help prevent cervical cancer in women
Compares misoprostol with placebo in non-pregnant women aged 25 or older with cervical screening findings.
Plain-language title generated from the registry record
Registry title: Use Misoprostol to Optimize Prevention of Cervical Cancer
Key facts
- Where
- Yaoundé, CameroonSee the site
Where in Cameroon
- Cameroon Baptist Convention Health Core, EtougEbe Baptist Hospital YaoundéYaoundé, CameroonTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Alabama at Birmingham
- Trial code
- NCT06669533
- Record updated
- 5 November 2026
- Original description
This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.Read full original descriptionShow less
Misoprostol to Optimizing Prevention of Cancer of the Cervix: A Double-Blind Randomized Controlled Trial
This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.
Inclusion: Diagnosis of Type 3 TZ confirmed on exam prior to randomization; Age 25 years or older.
Exclusion: With Type 1 or 2 TZ prior to randomization; History of hysterectomy; Currently pregnant; Any cancerous lesions; Active cervicitis.